AI-generated research brief — verify at source
Mepitel Film Shows No Long-Term PRO Advantage Over Standard Care, But Pigmentation and Pruritus Persist at Two Years
In a randomized controlled trial of 376 breast cancer patients followed for up to 24 months after radiation therapy, no significant long-term differences in skin-related patient-reported outcomes were detected between Mepitel Film and standard of care at any follow-up timepoint. Both groups showed persistent pigmentation changes and pruritus extending to two years post-treatment, indicating these are durable post-radiation symptoms independent of which preventive strategy was used.
What Was Studied
This study examined the long-term skin-related patient-reported outcomes (PROs) of breast cancer patients who had previously been enrolled in an RCT comparing Mepitel Film (MF), a silicone-based wound dressing, to standard of care (SOC) for the prevention of acute radiation dermatitis during radiotherapy. The aim was to determine whether any meaningful differences in skin symptoms between the two treatment approaches would emerge or resolve over a two-year post-treatment period, and to characterize which symptoms — if any — persisted beyond the acute phase.
How It Was Studied
This was a randomized controlled trial in which breast cancer patients undergoing radiation therapy were assigned to either Mepitel Film or standard of care for acute radiation dermatitis prevention. A total of 376 patients were included in the modified intention-to-treat analysis. Long-term follow-up was conducted via structured telephone interviews at 6, 12, and 24 months post-radiotherapy, during which participants completed two validated skin symptom instruments: the Skin Symptom Assessment (SSA) and the Radiation-induced Skin Reaction Assessment Scale (RISRAS). Longitudinal scores were compared to pre-treatment baseline values using generalized estimating equations with a Poisson distribution and log link function, with a Bonferroni-adjusted significance threshold of p < 0.001 applied to account for multiple comparisons.
What Was Observed
- No difference between treatments across time: Mepitel Film and standard of care produced statistically equivalent long-term skin-related PRO scores at all follow-up visits, regardless of whether patients had experienced mild (CTCAE Grade 0–1) or more severe (Grade 2–3) acute radiation dermatitis during treatment (no significant between-group differences at any timepoint).
- Persistent pigmentation changes in both groups: Patients in both the MF and SOC cohorts reported significantly worse pigmentation compared to baseline at 6, 12, and 24 months (p < 0.001 at each timepoint), suggesting this is a durable consequence of radiation that is not mitigated by either strategy.
- Pruritus and related symptoms elevated at 6 months: On the SSA, pruritus was significantly worse than baseline at 6 months (p < 0.001). On the RISRAS, tenderness, discomfort, pain, itchiness, and burning sensation were all significantly elevated at 6 months (p < 0.001), indicating a residual symptom burden in the early post-treatment window.
- Itchiness persists at 12 and 24 months: While most RISRAS symptom elevations resolved by 12 months, itchiness remained significantly worse than baseline at both 12 months (p = 0.0007) and 24 months (p < 0.001), indicating that this specific symptom follows a more prolonged trajectory than other acute dermatitis-related complaints.
Why This Matters
The findings establish that Mepitel Film carries no adverse long-term skin-related PRO profile relative to standard of care, supporting its continued use as a safe preventive strategy for acute radiation dermatitis. At the same time, the study identifies persistent pigmentation changes and chronic itchiness as ongoing patient concerns that are not resolved by either intervention and that appear independent of acute dermatitis severity. The authors note this warrants further investigation into the pathophysiological mechanisms driving these chronic symptoms, with the goal of developing targeted preventive strategies.
How to Read This Result
This is a well-powered RCT with a two-year follow-up horizon and a rigorous statistical correction for multiple comparisons; however, the exclusive reliance on telephone-based self-report — without concurrent physical examination data at long-term timepoints — means that subjective symptom persistence cannot be directly correlated with objective clinical signs, introducing some uncertainty about the clinical magnitude of the reported changes.
Limitations
The abstract does not explicitly report study limitations.